clinical trial · NCT06475300
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.·phase2·recruiting·n = 570
Non-small Cell Lung CancerNasopharyngeal CarcinomaSolid TumorBL-B01D1PD-1 Monoclonal AntibodyPemetrexed Disodium
brief summary
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.
started
Jun 25, 2024
primary completion
Jul 1, 2026
completion
Jul 1, 2026
last updated
May 6, 2026
official title
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol